{"product_id":"nvs-ansoff-analysis","title":"(NVS) Novartis AG ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Novartis AG Ansoff Matrix Analysis helps you quickly map growth options across market penetration, market development, product development, and diversification in a compact, actionable format; the page includes a real preview\/sample so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e9 therapeutic areas in Innovative Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis sells prescription drugs across 9 Innovative Medicines areas—ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolic disease—so market penetration means taking more share from the same specialist prescribers and patient pools. In FY2024, Innovative Medicines net sales were $37.7 billion, up 14% at constant currency, showing the base is already large. Growth here comes from deeper use, better switching, and stronger adherence in current therapy classes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz finished dosage forms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz finished dosage forms drive market penetration by selling more generic tablets, capsules, and injectables in existing markets through volume bids, tenders, and repeat prescribing. In 2024, Sandoz reported CHF 10.4 billion in net sales, showing the scale of its generic platform. This fits an Ansoff penetration play: take more share of the current retail generic opportunity, not new markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail generic drug base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz already sells retail generic drugs, so this Ansoff move is market penetration: push the same products harder in the same markets, not launch new ones. In 2024, Sandoz posted net sales of about USD 10.4 billion, showing a large base to grow from. The playbook is simple: stay price-competitive, widen pharmacy access, and win share from branded drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnti-infectives and antibiotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz, Novartis AG’s generics arm, uses anti-infectives and antibiotics as a market-penetration play in a mature category, selling into established hospital and retail supply chains. In 2024, Sandoz reported about USD 10.4 billion in net sales, so deeper share gains in the same therapeutic class can still move revenue. The upside is higher volume, not new therapy, by winning more tenders and more formulary slots.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, deeper share\u003c\/li\u003e\n\u003cli\u003eDriven by tenders and supply reliability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosimilars share expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz, Novartis AG's biosimilar business, used its protein- and biotech-derived portfolio to push into existing biologic markets and take share from originators. In 2024, Sandoz reported about USD 10.4 billion in net sales, showing scale to keep funding launch and manufacturing reach.\u003c\/p\u003e\n\u003cp\u003eIts biosimilar base matters because market penetration is faster when the product is already approved in the same therapy area, and price gaps can be large versus branded biologics. One clear aim: use the current plant network to widen access and lower unit cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand share in current biologic markets\u003c\/li\u003e\n\u003cli\u003eUse existing biosimilar plants\u003c\/li\u003e\n\u003cli\u003eCompete on price and access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis Grows by Winning More Share in Existing Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis’ market penetration is about taking more share in existing specialist and generic markets, not opening new ones. In FY2024, Innovative Medicines net sales were $37.7 billion and Sandoz net sales were CHF 10.4 billion, so the play is deeper prescribing, tender wins, and better access in current therapy areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003ePenetration cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative Medicines\u003c\/td\u003e\n\u003ctd\u003e$37.7B\u003c\/td\u003e\n\u003ctd\u003eMore share in current classes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz\u003c\/td\u003e\n\u003ctd\u003eCHF 10.4B\u003c\/td\u003e\n\u003ctd\u003eTenders and repeat volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Novartis AG’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a fast, structured Novartis AG Ansoff Matrix to simplify growth planning across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of Novartis sources to validate each Ansoff Matrix growth path and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal prescription-drug reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis AG posted 2025 net sales of CHF 50.3 billion, showing the scale behind its global prescription-drug reach. In Ansoff terms, market development means taking the same Innovative Medicines portfolio into more country markets and payer systems, not changing the drug itself. With 2025 sales support from a broad international footprint, Novartis can add access in new geographies and lift volume without redesigning the product. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz international generic rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz’s international generic rollout is a market development move: it takes the same finished-dosage medicines into more national markets through new registrations, local access, and wider channel reach. Sandoz already sells in about 100 markets, so the play is scale, not reinvention. In FY2024, Sandoz reported CHF 10.4 billion in net sales, showing the size of the base this expansion can build on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar access across new systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz biosimilars can enter new healthcare systems as reimbursement and prescribing rules open up, which is classic market development because the product stays the same while the market changes. In the U.S., biosimilars generated about USD 20.2 billion in savings in 2024 and USD 56.2 billion cumulatively since 2015, which supports faster adoption. That widens access without changing the core portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eThird-party API customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovartis already supplies active pharmaceutical ingredients to outside partners, so the same manufacturing base can reach more third-party customers and regional supply chains without building a new plant. In 2024, Novartis reported USD 50.3 billion in net sales, which shows the scale behind this market expansion play.\u003c\/p\u003e\n\u003cp\u003eThis is market development in Ansoff terms: the product base stays the same, but the customer base expands into external manufacturers that need reliable API supply.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame API base, more buyers.\u003c\/li\u003e\n\u003cli\u003eFits regional sourcing demand.\u003c\/li\u003e\n\u003cli\u003eScales without new molecule risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompleted small-molecule buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Novartis AG, completed small-molecule buyer growth now maps mainly to legacy Sandoz channels: the product stays the same, but sales expand by adding hospital groups, wholesalers, and new country partners. Sandoz posted 2024 net sales of US$10.4 billion, showing the scale of this buyer-base strategy. The 2023 spin-off means this market-development move is more a Sandoz play than a core Novartis AG one.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame molecules, wider buyer reach\u003c\/li\u003e\n\u003cli\u003eNew distributors, new geographies\u003c\/li\u003e\n\u003cli\u003eSandoz 2024 net sales: US$10.4bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis and Sandoz Grow Sales by Expanding Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis AG’s 2025 net sales of CHF 50.3 billion show the scale to push the same medicines into more country markets and payer systems. That is market development: product stays fixed, but access grows. Sandoz adds the clearest case, with 2024 net sales of US$10.4 billion and sales in about 100 markets. Wider geography means more volume, not new drugs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis AG 2025 net sales\u003c\/td\u003e\n\u003ctd\u003eCHF 50.3 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz 2024 net sales\u003c\/td\u003e\n\u003ctd\u003eUS$10.4 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz market reach\u003c\/td\u003e\n\u003ctd\u003eAbout 100 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNovartis AG Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, and the complete, editable version becomes available after payment. Get the full, detailed analysis immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInclisiran deal with Alnylam\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis AG’s licensing and collaboration deal with Alnylam Pharmaceuticals for inclisiran is a clear product development move: it brings a new medicine to market through partnership, not internal build. The drug already showed scale, with Leqvio sales of about US$754 million in 2024, up sharply from 2023, showing real demand for the LDL-C treatment. The deal covers development, production, and marketing, so Novartis can push the product faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTipifarnib plus alpelisib study\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis AG’s Tipifarnib plus alpelisib study with Kura Oncology is a product development move: it tests a new combination regimen in head and neck squamous cell carcinoma. The aim is to build clinical evidence for a fresh oncology use case, not just extend an old label. In 2025-2026, this kind of combo strategy is key because late-stage oncology success rates remain low, so data-rich partnerships can de-risk R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e9-therapy-area pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis AG’s Innovative Medicines spans nine therapeutic areas, so product development means adding new prescription drugs inside established markets like ophthalmology, neuroscience, and immunology. That breadth supports a steady pipeline model: in 2024, Novartis reported about $50.3 billion in net sales, showing the scale behind this approach. The same platform also covers hepatology, dermatology, respiratory, cardiovascular, renal, and metabolic disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew biosimilars from Sandoz\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew biosimilars at Sandoz fit product development: they add new biologic options to the same care areas, so the market stays the same while the portfolio gets refreshed. In 2024, Sandoz reported net sales of USD 10.4 billion, with biosimilars a key growth driver for the standalone company. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, new biologic options\u003c\/li\u003e\n\u003cli\u003eSupports portfolio refresh\u003c\/li\u003e\n\u003cli\u003eUses Sandoz biosimilar scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew dosage-form medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz, the generics and biosimilars arm now separate from Novartis AG, uses product development to launch new dosage-form medicines: new formulations, completed small-molecule medicines, and finished dosage forms that move faster from lab to supply. In 2024, Sandoz reported about US$10.4 billion in net sales and a 20.9% core EBITDA margin, showing scale behind this pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew formulations extend product reach.\u003c\/li\u003e\n\u003cli\u003eFinished dosage forms drive launches.\u003c\/li\u003e\n\u003cli\u003eManufacturing turns R\u0026amp;D into supply.\u003c\/li\u003e\n\u003cli\u003e2024 net sales: about US$10.4 billion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis Expands Fast: Big Sales, Deep Pipeline, New Drug Regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis AG uses product development to add new drugs in its core therapy areas, with 2025 net sales of about US$52 billion and a deep pipeline across oncology, immunology, and neuroscience. Leqvio and combo trials like tipifarnib plus alpelisib show how licensed assets and new regimens can expand the portfolio fast. Sandoz also fits this move with new biosimilars and dosage forms.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis AG net sales\u003c\/td\u003e\n\u003ctd\u003e~US$52bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz net sales\u003c\/td\u003e\n\u003ctd\u003e~US$10.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology manufacturing services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz’s biotechnology manufacturing services once widened Novartis beyond pure drug sales, adding a service-based revenue stream tied to external biotech demand. \u003c\/p\u003e\n\u003cp\u003eBut Sandoz was spun off in 2023, so this diversification no longer sits inside Novartis AG. \u003c\/p\u003e\n\u003cp\u003eNovartis reported 2025 net sales of $50.3 billion, so its current growth relies more on medicines than on manufacturing services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI supply to other entities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz’s API sales to other entities move Novartis AG into a broader B2B layer: it monetizes upstream manufacturing, not just end-patient demand. In 2024, Sandoz posted net sales of about USD 10.4 billion, showing the scale of this channel. That makes the move a real diversification play, adding revenue from external pharma partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtein and biotech products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz’s protein- and biotechnology-derived products push Novartis beyond small-molecule generics and into biologics, where development is slower, more regulated, and customer buying is different. Biologics already make up a large share of modern pharma spending, so this mix helps reduce dependence on one product type and one pricing cycle. It also spreads risk across more therapy areas and margin profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRNAi collaboration with Alnylam\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovartis AG's inclisiran deal with Alnylam is a clear diversification move: it links Novartis to RNAi, a modality outside its small-molecule core. The asset's twice-yearly maintenance dosing also broadens the market beyond classic oral drugs. Strategic partnering lowers platform risk while opening new growth lanes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRNAi expands product scope.\u003c\/li\u003e\n\u003cli\u003eAlnylam adds platform know-how.\u003c\/li\u003e\n\u003cli\u003ePartnering limits development risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology combo partnership with Kura\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Kura Oncology collaboration moves Novartis AG into a precision-oncology combo path for head and neck squamous cell carcinoma, a niche with about 890,000 new global cases a year. It is diversification through partnered R\u0026amp;D: Novartis adds exposure to a distinct clinical segment and a different innovation route without funding the whole program alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew solid-tumor niche exposure\u003c\/li\u003e\n\u003cli\u003eLower capital risk than buying it outright\u003c\/li\u003e\n\u003cli\u003ePipeline optionality from shared R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis Diversification Now Runs Through Its Drug Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification in Novartis AG is now narrow: after the 2023 Sandoz spin-off, the group leans on drug pipelines, not manufacturing services. In 2025, Novartis AG posted $50.3 billion net sales, so growth still comes mainly from medicines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025\/2024 data\u003c\/th\u003e\n\u003cth\u003eRole in diversification\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz spin-off\u003c\/td\u003e\n\u003ctd\u003eCompleted 2023\u003c\/td\u003e\n\u003ctd\u003eExited service-led diversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis AG net sales\u003c\/td\u003e\n\u003ctd\u003e$50.3 billion in 2025\u003c\/td\u003e\n\u003ctd\u003eCore drug-led revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInclisiran RNAi deal\u003c\/td\u003e\n\u003ctd\u003ePartnered asset\u003c\/td\u003e\n\u003ctd\u003eExpands modality mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKura oncology deal\u003c\/td\u003e\n\u003ctd\u003ePrecision oncology\u003c\/td\u003e\n\u003ctd\u003eAdds niche pipeline exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSo the current diversification story is partner-led R\u0026amp;D, not broad business-line expansion.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234750275849,"sku":"nvs-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nvs-ansoff-matrix.webp?v=1785726955","url":"https:\/\/dcfanalyst.com\/products\/nvs-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}